Sandy Visit 1: A 33-year-old woman starting treatment for newly diagnosed rheumatoid arthritis


Sandy Visit 1: A 33-year-old woman starting treatment for newly diagnosed rheumatoid arthritis

Topic: Rheumatology
Relevant Terms: Early Rheumatoid Arthritis, Rheumatoid Arthritis
Primary Audience: Rheumatologists and other clinicians who treat patients with RA
Launch Date: 17-Dec-13
Credits: 0.5 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Achieving RA Treatment Goals: Maximizing Safety and Efficacy

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Discuss methods for utilizing RA therapies in a way that maximizes both safety and efficacy
  2. Outline barriers to using available RA therapies to achieve optimal disease control
  3. Discuss RA treatment goals and the clinical implications of seeking a state of clinical remission as a primary target for treatment of RA


    Michael York, MD
    Assistant Professor in Medicine
    Section of Rheumatology
    Boston University Medical Campus
    Boston, MA
    Naomi Amudala, MSN, RN, FNP-BC
    Clinical Instructor and Nurse Practitioner
    Vasculitis Center/Rheumatology
    Boston University School of Medicine
    Boston, MA
    Tuhina Neogi, MD, PhD
    Associate Professor of Medicine and of Epidemiology
    Boston University School of Medicine
    Boston, MA
    Rheumatoid arthritis (RA) is an autoimmune condition characterized by chronic inflammation primarily affecting the lining of the joints but also affecting other organs. Patients who have RA may suffer from loss of functional capacity as their disease progresses, and many experience reduced health-related quality of life. RA treatment goals are aimed at controlling pain and inflammation and, ultimately, slowing the progression of joint destruction and disability. This activity will help clinicians improve outcomes in patients with RA by expanding their skills to 1) initiate treatment as early as possible with a DMARD, 2) appropriately utilize the full range of medications available for the management of RA, and 3) ensure appropriate, individualized treatment targets are reached according to new ACR therapy guidelines.
    This activity is an interactive case-based experience that approximates the assessment and decision-making (prioritization, diagnostic and therapeutic options) inherent in day-to-day patient care. The format integrates interaction among faculty members who represent different members of the health care team and who provide learners with information and commentary that can be immediately applied to their practice.
    The educational design of this activity addresses the needs of rheumatologists and other clinicians involved in the treatment of patients with RA.
    Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 
    Michael York, MD: Nothing to disclose 
    Naomi A. Amudala, MSN, RN, FNP-BC: Nothing to disclose 
    Tuhina Neogi, MD, PhD: Nothing to disclose 
    This activity is jointly sponsored by Global Education Group and MCM Education.
    Planning Committee Disclosures
    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

    Ashley Marostica, RN, MSN: Nothing to disclose
    Amanda Glazar, PhD: Nothing to disclose 
    Anne Jacobson (MCM Education writer): Nothing to disclose 

    Disclosure of Unlabeled Use 
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and MCM Education do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and MCM Education. Global is accredited by the ACCME to provide continuing medical education for physicians. 

    Global Education Group designates this enduring educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page.
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the post-test and activity evaluation.
    • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 75% or higher on the post-test to receive credit for this activity.
    • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. 
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 5.0+ for Mac OSX 10.5 and above

    For video playback, install the latest version of Flash or Quicktime.
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above


    Release Date: December 17, 2013
    Expiration Date: December 16, 2014
    Estimated time to complete: 0.5 hours
    There is no fee for this educational activity.
    For information about the accreditation of this program, please contact Global at 303-395-1782 or

    Program Code: 

    This continuing medical education activity is sponsored by independent educational grants from AbbVie, Inc. and Amgen, Inc.